期刊
JOURNAL OF ALZHEIMERS DISEASE
卷 16, 期 1, 页码 49-57出版社
IOS PRESS
DOI: 10.3233/JAD-2009-0925
关键词
Alzheimer's disease; amyloid-beta; hypertension; oligomerization
资金
- Altschul Foundation
- Dr. Robert C. Atkins Foundation
- James J. Peters VA Geriatrics, Research, Education and Clinical Center Program
- National Institute of Aging [AG02219]
- NATIONAL INSTITUTE ON AGING [P01AG002219] Funding Source: NIH RePORTER
Recent studies suggest that certain cardiovascular antihypertensive agents decrease the incidence of Alzheimer's disease. Based on this evidence and the fact that A beta aggregation into high-molecular-weight-soluble oligomeric A beta species is known to directly induce cognitive impairment, we tested the possibility that certain antihypertensive compounds may affect the progression of Alzheimer's disease, at least in part by influencing the formation of A beta oligomers. High throughput screening of 55 commercially available antihypertensive drugs identified four compounds that significantly reduced A beta(1-42) oligomerization in a dose dependent manner. These four compounds, furosemide (diuretic), nitrendipine (calcium channel blocker), candesartan cilextil (angiotensin II receptor antagonist) and diazoxide (vasodilator) showed no detectable A beta lowering activities in primary neuron cultures generated from Tg2576 mouse embryos. However, furosemide, nitrendipine and candesartan cilextil prevented oligomerization of both A beta(1-40) and A beta(1-42) in vitro. Furosemide also dissociated pre-aggregated A beta(1-42) oligomers. Furthermore, short term furosemide treatment resulted in decreased amount of A beta oligomers in the brain of Tg2576 mice. Our studies suggest that certain antihypertensive compounds may prevent AD-type neuropathology through inhibition of A beta oligomer formation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据